We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AQSZF market cap is 2.18M. The company's latest EPS is CAD -0.0224 and P/E is -0.89.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 1.63M | 2.59M | 2.72M | 1.38M | 254k |
| Operating Income | -2.32M | -604k | -1.06M | -2.16M | -2.36M |
| Net Income | -3.11M | -1.05M | -1.81M | -3.21M | -2.97M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 1.67M | 3.13M | 4.35M | 1.69M | 1.09M |
| Total Liabilities | 2.55M | 2.56M | 2.56M | 3.07M | 5.38M |
| Total Equity | -877k | 574k | 1.79M | -1.38M | -4.29M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -1.63M | -805k | -1.17M | -1.95M | -2.3M |
| Investing | -3k | -12k | -508k | N/A | N/A |
| Financing | 1.75M | 2.05M | 2.4M | -189k | 2.22M |
| Market Cap | 2.18M |
| Price to Earnings Ratio | -0.89 |
| Price to Sales Ratio | 10.53 |
| Price to Cash Ratio | 15.38 |
| Price to Book Ratio | -0.62 |
| Dividend Yield | - |
| Shares Outstanding | 132.63M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 5.3k |
| 52 Week Change | -52.73% |
| 52 Week High | 0.04 |
| 52 Week Low | 0.0079 |
| Spread (Intraday) | 0.01 (64%) |
| Company Name | Aequus Pharmaceuticals Inc (QB) |
| Address |
suite 2600, 595 burrard street vancouver, british columbia V7X 1L3 |
| Website | https://www.aequuspharma.ca |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
